Age-Related Macular Degeneration (ARMD) Terminated Phase 2 Trials for Ranibizumab (DB01270)

Also known as: Age-related macular degeneration / Macular Degeneration / Senile macular degeneration / Macular degeneration senile / Macular degeneration (senile) of retina, unspecified

IndicationStatusPhase
DBCOND0034150 (Age-Related Macular Degeneration (ARMD))Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02387957A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)Treatment
NCT00766337Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular DegenerationTreatment
NCT00857259The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular DegenerationTreatment
NCT00395057A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular DegenerationTreatment